Does RAVULIZUMAB-CWVZ Cause Poor venous access? 115 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 115 reports of Poor venous access have been filed in association with RAVULIZUMAB-CWVZ. This represents 1.1% of all adverse event reports for RAVULIZUMAB-CWVZ.
115
Reports of Poor venous access with RAVULIZUMAB-CWVZ
1.1%
of all RAVULIZUMAB-CWVZ reports
1
Deaths
18
Hospitalizations
How Dangerous Is Poor venous access From RAVULIZUMAB-CWVZ?
Of the 115 reports, 1 (0.9%) resulted in death, 18 (15.7%) required hospitalization.
Is Poor venous access Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RAVULIZUMAB-CWVZ. However, 115 reports have been filed with the FAERS database.
What Other Side Effects Does RAVULIZUMAB-CWVZ Cause?
Fatigue (1,472)
Asthenia (727)
Headache (639)
Drug ineffective (570)
Off label use (451)
Muscular weakness (422)
Dyspnoea (414)
Malaise (353)
Haemoglobin decreased (346)
Myasthenia gravis (338)
What Other Drugs Cause Poor venous access?
VEDOLIZUMAB (1,043)
INFLIXIMAB (917)
INFLIXIMAB-DYYB (782)
ECULIZUMAB (555)
HUMAN IMMUNOGLOBULIN G (504)
NATALIZUMAB (422)
RITUXIMAB (299)
TOCILIZUMAB (287)
METHOTREXATE (257)
ABATACEPT (249)
Which RAVULIZUMAB-CWVZ Alternatives Have Lower Poor venous access Risk?
RAVULIZUMAB-CWVZ vs REBAMIPIDE
RAVULIZUMAB-CWVZ vs REBETOL
RAVULIZUMAB-CWVZ vs REBIF
RAVULIZUMAB-CWVZ vs REBOXETINE
RAVULIZUMAB-CWVZ vs RECLAST